Our Terms of Service and Privacy Policy have changed.

By continuing to use this site, you are agreeing to the new Privacy Policy and Terms of Service.

Zogenix Inc (NASDAQ:ZGNX)

19.76
Delayed Data
As of Sep 04
 +0.13 / +0.66%
Today’s Change
8.56
Today|||52-Week Range
21.65
+80.29%
Year-to-Date
SECTOR
Health Technology
INDUSTRY
Pharmaceuticals: Other
MARKET CAP
$379.5M

Company Description

Zogenix, Inc. is a pharmaceutical company, which is engaged in commercializing and developing products for the treatment of central nervous system disorders and pain with novel drug delivery platforms. The company's product portfolio includes: Sumavel DosePro, Zohydro and Relday. The Sumavel DosePro product offers fast-acting, easy-to-use subcutaneous administration of sumatriptan for the acute treatment of migraine and cluster headache. The Zohydro product is a 12-hour extended-release formulation of hydrocodone without acetominophen for the treatment of moderate to severe chronic pain requiring around-the-clock opioid therapy. The Relday product is a proprietary, long-acting injectable formulation of risperidone using durect's SABER controlled-release formulation technology in combination with its DosePro needle-free, subcutaneous drug delivery system. Zogenix was founded by Stephen J. Farr, Cam L. Garner, Roger L. Hawley, Bret E. Megargel, Jonathan M. Rigby and John J. Turanin on May 11, 2006 and is headquartered in San Diego, CA.

Contact Information

Zogenix, Inc.
12400 High Bluff Drive
San Diego California 92130
P:(858) 259-1165
Investor Relations:

Employees

Shareholders

Mutual fund holders31.39%
Other institutional24.32%
Individual stakeholders0.33%

Top Executives

Stephen J. FarrPresident, Chief Executive Officer & Director
Ann D. RhoadsCFO, Secretary, Treasurer & Executive VP
Jeff D. DurflingerVP-Technical Operations & Product Supply
Bradley S. GalerChief Medical Officer & Executive Vice President
Arnold R. GammaitoniVice President-Medical & Scientific Affairs